49 results on '"Buecklein, Veit"'
Search Results
2. Applying the EHA/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality
3. Prognostic value of pre-infusion tumor growth rate for patients with lymphoma receiving chimeric antigen receptor T-cell therapy
4. CD19 CAR T cells are an effective therapy for posttransplant relapse in patients with B-lineage ALL: real-world data from Germany
5. Potential synergy between radiotherapy and CAR T-cells - a multicentric analysis of the role of radiotherapy in the combination of CAR T cell therapy
6. Safety and tolerability of AMG 330 in adults with relapsed/refractory AML: a phase 1a dose-escalation study
7. T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals
8. GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany
9. Neurofilament light chain serum levels correlate with the severity of neurotoxicity after CAR T-cell treatment
10. Early quantification of anti-CD19 CAR T cells by flow cytometry predicts response in R/R DLBCL
11. Results of the Risk-Adapted, MRD-Stratified GMALL Trial 08/2013 in 281 T-ALL / T-Lbl Patients: Excellent Outcome of Standard Risk Thymic T-ALL
12. Distinguishing Early Infections from CRS with Routine and Exploratory Serum Proteomics and the HT10 Score Following CD19 CAR-T for Relapsed/Refractory B-NHL
13. Trial in Progress: An Open-Label Phase II Study of Relatlimab with Nivolumab in Combination with 5-Azacytidine for the Treatment of Patients with Relapsed/Refractory and Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia (AARON)
14. The Race Is on: BiTE Vs CART As FLT3-Directed Immunotherapies in AML
15. Inferior Outcomes of EU Vs. US Patients with Relapsed/Refractory Large B-Cell Lymphoma after CD19 CAR T-Cell Therapy Are Associated with Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization and CAR-T Product Selection
16. Uncovering the Enemy: Single-Cell Transcriptional Profiling of Measurable Residual Disease (MRD) Cells
17. Biphasic Neutrophil Recovery after CD19 CART in R/R LBCL Is Associated with Superior PFS/OS, Robust CAR T-Cell Expansion in Relation to Baseline Tumor Volume, and a Decrease of Systemic Inflammation over Time
18. CD19-CAR-T Cells Are Effective and Safe Treatment of Post-Transplant Relapse in Pediatric and Young Adult Patients with B-Lineage ALL: Real-World Data from Germany
19. Body Composition and Immunonutritional Status Impact Survival Outcomes after CD19 CAR T-Cell Therapy
20. Oligoclonal T-cell expansion in a patient with bone marrow failure after CD19 CAR-T therapy for Richter-transformed DLBCL
21. Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy
22. Erratum:Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working Party (HemaSphere (2022) 6:1 (e676) DOI: 10.1097/HS9.0000000000000676)
23. Inferior Outcomes of EU Vs. US Patients with Relapsed/Refractory Large B-Cell Lymphoma after CD19 CAR T-Cell Therapy Are Associated with Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization and CAR-T Product Selection
24. CD19-CAR-T Cells Are Effective and Safe Treatment of Post-Transplant Relapse in Pediatric and Young Adult Patients with B-Lineage ALL: Real-World Data from Germany
25. Results of the Risk-Adapted, MRD-Stratified GMALL Trial 08/2013 in 281 T-ALL/T-Lbl Patients: Excellent Outcome of Standard Risk Thymic T-ALL
26. Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working Party
27. CD33 BiTE ® Construct Mediated Immunological Synapse Formation and Downstream Signaling in T Cells Is Dependent on Expression of Costimulatory Molecules on Target Cells
28. Treatment-Free Intervals during CD19xCD3 BiTE ® Construct-Mediated T-Cell Stimulation Induce Functional Reinvigoration and Transcriptional Reprogramming of Exhausted T Cells
29. The CAR-Hematotox Identifies Patients at High Risk for Prolonged Neutropenia, Infectious Complications and Prolonged Hospitalization Following CD19-CART in R/R LBCL
30. "My T Cell": A Smartphone Application for Guidance of CAR T Logistics and Management of CAR T & BiTE Related Toxicities
31. Augmenting Efficacy of T-Cell Bispecific Antibodies in AML through a Tumor Stroma-Targeted 4-1BB Agonist
32. Evolving Exhaustion of T Cells during the Course of the Disease in AML Can be Abrogated By CD33 BiTE ® Construct Mediated Cytotoxicity
33. High Bacterial Abundances of Dorea and Pediococcus in the Gut Microbiome Linked to Expansion, Immune Checkpoint Expression and Efficacy of CD19-Directed CAR T-Cells in Patients with r/r DLBCL
34. Immune infiltrates in patients with localised high-risk soft tissue sarcoma treated with neoadjuvant chemotherapy without or with regional hyperthermia: A translational research program of the EORTC 62961-ESHO 95 randomised clinical trial
35. Two Players, One Goal: BiTE ® Vs CART Targeting FLT3 in AML
36. Distinct Temporal Dynamic Serum Metabolite Profiles Characterize Treatment Response and Early Toxicity after B-Cell Lymphoma Directed CAR-T-Cell Therapy
37. Early Real Time Quantification of CD19. CAR T Cells By Flow Cytometry As a Predictive Biomarker for Response in Patients with R/R LBCL
38. Phenotypic, Transcriptomic and Proteomic Characteristics of CAR T-Cell Dysfunction Are Associated with Inferior CAR T-Cell Expansion and Treatment Failure in r/r B-NHL
39. Beyond Mitigating Immune-Related Adverse Events: Glucocorticoids Ameliorate Bispecific Antibody-Mediated T-Cell Exhaustion I n Vitro
40. CNS Irradiation in Adult De Novo B-Precursor ALL / Lbl: Results of the Randomized GMALL Trial 08/2013 Indicate Potential Antileukemic Efficacy
41. Single-Cell Transcriptomic Profiling of T Cells from Blinatumomab-Treated Patients with B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) Reveals Circulating CD8 T Cell Subsets Associated with Treatment Response
42. Applying the Novel EHA/EBMT Grading System for Icaht Following CAR-T Therapy: Comparative Incidence across Disease Entities and Association with Infections and Mortality
43. Accomplices in Cure: Blinatumomab + Dasatinib Reduces TCR Signaling and Effector Function Stronger Than Ponatinib and Ameliorates T-Cell Exhaustion
44. The Battle within: AML´s p53 Strategies to Evade T-Cell Attack
45. Impact of Sex on Clinical Outcomes after CD19 CAR T-Cell Therapy for Large B-Cell Lymphoma: Response and Survival Are Significantly Superior in Female Compared to Male Patients
46. CD33-TIM3 Dual CAR T Cells: Enhancing Specificity While Maintaining Efficacy Against AML
47. Influence of modified Lugano criteria by pre-infusion tumor kinetics on early survival prediction for patients with lymphoma under chimeric antigen receptor T-cell therapy.
48. Technical Aspects of Flow Cytometry‐based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working Party.
49. High Bacterial Abundances of Doreaand Pediococcusin the Gut Microbiome Linked to Expansion, Immune Checkpoint Expression and Efficacy of CD19-Directed CAR T-Cells in Patients with r/r DLBCL
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.